Pay in 4 interest-free payments of $6.04 Learn more
Ships within 48 hours · Estimated delivery Sep 27 - Oct 2
GLP-1 Offboarding - EVERY consumer stops taking GLP-1s at some point based upon Numerator data & research from equity analysts (see prior posts on this)
Retatrutide is a triple agonist (GLP-1 + GIP + glucagon), tirzepatide is a dual agonist (GLP-1 + GIP), and semaglutide is a single agonist (GLP-1)
The product catalog covers grey-market research peptide listings and FDA-pathway GLP-1 medication resources as separate categories so visitors can distinguish laboratory research context from licensed medical consultation pathways
Structural basis for the therapeutic advantage of dual and triple agonists at the human GIP, GLP-1 or GCG receptors
US$ 26.20
US$ 24.14
US$ 24.00
US$ 23.73
US$ 29.60
US$ 27.44
US$ 23.43
